

Please Direct All Correspondence to Customer Number **20995**

TRANSMITTAL LETTER
INFORMATION DISCLOSURE STATEMENT

Applicant : Sallberg, Matti
App. No : 10/773,628
Filed : February 5, 2004
For : GLYCOSYLATED SPECIFICITY
EXCHANGERS
Examiner : Unassigned
Art Unit : 1616

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

February 24, 2005

(Date)


Eric S. Furman, Ph.D., Reg. No. 45,664


Mail Stop Amendment


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement and PTO/SB/08 equivalent listing references for consideration:
 - (X) Listing seven (7) references.
 - (X) Enclosing five (5) references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.


Eric S. Furman, Ph.D.
Registration No. 45,664
Attorney of Record
Customer No. 20,995
(619) 235-8550



INFORMATION DISCLOSURE STATEMENT

Applicant : Sallberg, Matti
App. No : 10/773,628
Filed : February 5, 2004
For : GLYCOSYLATED SPECIFICITY
EXCHANGERS
Examiner : Unassigned
Art Unit : 1616

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

February 24, 2005

(Date)


Eric S. Furman, Ph.D., Reg. No. 45,664

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is an Information Disclosure Statement by Applicant (PTO/SB/08 equivalent) listing seven references to be considered by the Examiner. Also enclosed are five copies of foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required. If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 2/24/05

By: 

Eric S. Furman, Ph.D.
Registration No. 45,664
Attorney of Record
Customer No. 20,995
(619) 235-8550

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application No. 10/773,628
 Filing Date February 5, 2004
 First Named Inventor Sallberg, Matti
 Art Unit 1616
 Examiner Unknown
 Attorney Docket No. TRIPEP.056A

(Multiple sheets used when necessary)

SHEET 1 OF 1

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	US5714332	02-03-1998	Lussow, et al.	
	2	US5922548	07-13-1999	Lussow, et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
	3	WO0182546A1	11-01-2001	INTERDIGITAL TECHNOLOGY CORPORATION		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	4	Ennas et al., "The Human ALL-1/Mll/HRX Antigen is Predominantly Localized in the Nucleus of Resting and Proliferating Peripheral Blood Mononuclear Cells" Cancer Research 57, 2035-2041, May 15, 1997	
	5	Galili et al., "Evolutionary relationship between the natural anti-Gal antibody and the Gal α 1 \rightarrow 3Gal epitope in primates" Proc. Natl. Acad. Sci. Vol. 84, pp. 1369-1373, March 1987 Immunology	
	6	Galili et al., "Human natural anti- α -galactosyl IgG: the specific recognition of α (1 \rightarrow 3)-linked galactose residues, J. Exp. Med., Vol. 162, Aug. 1985, pp. 573-582	
	7	Galili et al., "One percent of human circulating B Lymphocytes are capable of producing the natural anti-gal antibody" Blood, Vol. 82, No. 8, October 15, 1993 pp. 2485-2493	

S:\DOCS\ESF\ESF-8687.DOC 013105

Examiner Signature	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

T¹ - Place a check mark in this area when an English language Translation is attached.